This was a placebo-controlled, double-blind, randomized trial designed with the aim of establishing whether curcumin influenced the duration of treatment interruption and rate of prostatic specific antigen(PSA) progression, compared with placebo among men with prostate cancer receiving intermittent androgen deprivation therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
107
Duration of treatment interruption with or without curcumin
To determine whether the period from the first interruption of the androgen deprivation therapy to the time when androgen deprivation therapy needs to be retreated differ between curcumin group and placebo group
Time frame: up to 42 months
Mean change in PSA(ng/ml) from baseline between curcumin group versus placebo
Measure the mean change of PSA at each point from the baseline and compare differences between the two groups
Time frame: 0,1,2,3,4,5,6,12,18,30,42 months
Mean change in testosterone(ng/ml) from baseline between curcumin group versus
Measure the mean change of testosterone at each point from the baseline and compare differences between the two groups
Time frame: 0,1,2,3,4,5,6,12,18,30,42 months
Adverse events
Adverse events were recorded according to the Common Terminology Criteria for Adverse Events(CTCAE). Vital sign, blood test and urine analysis were also performed.
Time frame: 0,1,2,3,4,5,6,12,18,30,42 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.